Our data show that IL-6 deletion in ECs significantly improved animal survival in the mice bearing the genetically induced GBM tumors, leading to an increase in overall survival time by 45% (19 versus 27.5 days, in control and tamoxifen-treated Chd5-CreERT2;Il6fl/fl mice, Fig. 8a). The gene discussed is CHD5; the disease is glioblastoma.